Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2019 Oct 3;19(1):147–156. doi: 10.1158/1535-7163.MCT-18-1202

Figure 1. Combination treatment of trebananib and MET kinase inhibitor results in significant inhibition of metastases and increased survival in the metastatic RP-R-02LM.

Figure 1.

(A) Non survival subcutaneous study tumor growth curves show no significant difference across the cohorts. (B) Non survival subcutaneous study end-point tumor weights show no significant difference in tumor size (n = 6 mice per group). (C) Non survival subcutaneous study representative H&E staining of the lungs show a striking reduction in the presence of lung metastases in the trebananib and combination groups. Scale bar = 200 μm (D-E) Non survival subcutaneous study, blinded analysis of the average number of lung metastases and metastatic diameter showed a significant reduction in the presence of metastases in the combination group as compared to all other groups (n = 6 mice per group; n = 136–173 images per group). (F) Orthotopic study-Kaplan-Meier survival curve showing a significant increase in the survival of both the combination and trebananib treatment alone compared to the vehicle cohort. (G) Subcutaneous study-Kaplan-Meier survival curve revealing a strikingly significant increase in the survival rates of mice in the combination group as compared to all other groups in the study. Results are given as mean + SEM. *p-value = <0.05, **p-value = <0.005, ***p-value = <0.001, ****p-value = <0.0001.